Journal: Frontiers in Pharmacology
Article Title: Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer
doi: 10.3389/fphar.2020.616251
Figure Lengend Snippet: Berberine sensitizes DDP-resistance gastric cancer cells to cisplatin treatment. (A) MTT assay determined the cell viability of BGC-823 cells after cisplatin treatment or BGC-823/DDP cells after cisplatin or cisplatin + berberine treatments. (B) MTT assay determined the cell viability of SGC-7901 cells after cisplatin treatment or SGC-7901/DDP cells after cisplatin or cisplatin + berberine treatments. N = 3; ** p < 0.01 compared to parental cell group; # p < 0.05 and ## p < 0.01 compared to SGC-7901/DDP cells treated with DDP alone. (C,D) Western blot analysis of MDR1 and MRP1 protein levels in BGC-823/DDP and SGC-7901 cells after different concentrations of berberine treatments. * p < 0.05 and ** p < 0.01 compared to Blank group ( n = 3).
Article Snippet: The concentrations and the sources of the primary antibodies were shown below: β-actin (1:2,000; Cell Signaling Technology, Danvers, United States), cleaved caspase-3 (1:1,000; Cell Signaling Technology), cleaved caspase-9 (1:1,000, Cell Signaling Technology), Bax (1:1,000; Cell Signaling Technology), multidrug resistance-associated protein 1 (MRP1; 1:1,000; Cell Signaling Technology), multi-drug resistance-1 (MDR1; 1:1,500; Cell Signaling Technology), phosphorylated (phospho)-PI3K (1:1,000; Cell Signaling Technology), PI3K (1:1,000; Cell Signaling Technology), phospho-AKT (1:1,000; Cell Signaling Technology), AKT (1:1,000; Cell Signaling Technology), phospho-mTOR (1:1,000; Cell Signaling Technology) and mTOR (1:1,000; Cell Signaling Technology).
Techniques: MTT Assay, Western Blot